Shared Mechanisms between Cardiovascular Disease and NAFLD.

IF 4.3 3区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Seminars in liver disease Pub Date : 2022-11-01 DOI:10.1055/a-1930-6658

Daniel Q Huang, Michael Downes, Ronald M Evans, Joseph L Witztum, Christopher K Glass, Rohit Loomba

{"title":"Shared Mechanisms between Cardiovascular Disease and NAFLD.","authors":"Daniel Q Huang, Michael Downes, Ronald M Evans, Joseph L Witztum, Christopher K Glass, Rohit Loomba","doi":"10.1055/a-1930-6658","DOIUrl":null,"url":null,"abstract":"<p><p>The burden of nonalcoholic fatty liver disease (NAFLD) is rising globally. Cardiovascular disease is the leading cause of death in patients with NAFLD. Nearly half of individuals with NAFLD have coronary heart disease, and more than a third have carotid artery atherosclerosis. Individuals with NAFLD are at a substantially higher risk of fatal and nonfatal cardiovascular events. NAFLD and cardiovascular disease share multiple common disease mechanisms, such as systemic inflammation, insulin resistance, genetic risk variants, and gut microbial dysbiosis. In this review, we discuss the epidemiology of cardiovascular disease in NAFLD, and highlight common risk factors. In addition, we examine recent advances evaluating the shared disease mechanisms between NAFLD and cardiovascular disease. In conclusion, multidisciplinary collaborations are required to further our understanding of the complex relationship between NAFLD and cardiovascular disease and potentially identify therapeutic targets.</p>","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828940/pdf/nihms-1845665.pdf","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in liver disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-1930-6658","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 11

Abstract

The burden of nonalcoholic fatty liver disease (NAFLD) is rising globally. Cardiovascular disease is the leading cause of death in patients with NAFLD. Nearly half of individuals with NAFLD have coronary heart disease, and more than a third have carotid artery atherosclerosis. Individuals with NAFLD are at a substantially higher risk of fatal and nonfatal cardiovascular events. NAFLD and cardiovascular disease share multiple common disease mechanisms, such as systemic inflammation, insulin resistance, genetic risk variants, and gut microbial dysbiosis. In this review, we discuss the epidemiology of cardiovascular disease in NAFLD, and highlight common risk factors. In addition, we examine recent advances evaluating the shared disease mechanisms between NAFLD and cardiovascular disease. In conclusion, multidisciplinary collaborations are required to further our understanding of the complex relationship between NAFLD and cardiovascular disease and potentially identify therapeutic targets.

查看原文本刊更多论文

心血管疾病和NAFLD的共同机制。

非酒精性脂肪性肝病(NAFLD)的负担正在全球范围内上升。心血管疾病是NAFLD患者死亡的主要原因。近一半的NAFLD患者患有冠心病，超过三分之一的患者患有颈动脉粥样硬化。NAFLD患者发生致死性和非致死性心血管事件的风险更高。NAFLD和心血管疾病有多种共同的发病机制，如全身性炎症、胰岛素抵抗、遗传风险变异和肠道微生物生态失调。在这篇综述中，我们讨论了NAFLD中心血管疾病的流行病学，并强调了常见的危险因素。此外，我们研究了评估NAFLD和心血管疾病之间共同疾病机制的最新进展。总之，需要多学科合作来进一步了解NAFLD与心血管疾病之间的复杂关系，并潜在地确定治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in liver disease 医学-胃肠肝病学

CiteScore

8.20

自引率

2.40%

发文量

期刊介绍： Seminars in Liver Disease is a quarterly review journal that publishes issues related to the specialties of hepatology and gastroenterology. As the premiere review journal in the field, Seminars in Liver Disease provides in-depth coverage with articles and issues focusing on topics such as cirrhosis, transplantation, vascular and coagulation disorders, cytokines, hepatitis B & C, Nonalcoholic Steatosis Syndromes (NASH), pediatric liver diseases, hepatic stem cells, porphyrias as well as a myriad of other diseases related to the liver. Attention is also given to the latest developments in drug therapy along with treatment and current management techniques. Seminars in Liver Disease publishes commissioned reviews. Unsolicited reviews of an exceptional nature or original articles presenting remarkable results will be considered, but case reports will not be published.